Authors
Latest:
Pembrolizumab in Advanced Gastric Cancer TreatmentKei Muro, MD, discusses phase II and III trials which examine pembrolizumab as a treatment for patients with advanced gastric cancer.
Latest:
Dr. Keith C. Bible on Treatments Beyond First-Line Lenvatinib in Thyroid CancerBible says most oncologists would consider lenvatinib as a first-line therapy for patients who require systemic therapy where there are not suitable, focal palliative options.
Latest:
Combination Regimen Options Under Investigation in MelanomaKeith T. Flaherty, MD, discusses the combination regimens and the potential role for a 3-drug regimen as treatment for patients with melanoma. He says investigators have been searching for new combination strategies beyond the combination of BRAF and MEK inhibitors.
Latest:
The Link Between Helicobacter Pylori and Gastric CancerKeith T. Wilson, MD, Thomas F. Frist, Sr. Chair in Medicine, Professor, Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center explains the link between helicobacter pylori (H pylori) and gastric cancer.
Latest:
Dr. Keith Wilson on the Role of Helicobacter Pylori in Gastrointestinal Cancer<div style="color:#003668"><em>"When there is a mismatch between the human genetics and bacterial genetics, this may be one of the factors that leads to gastrointestinal cancer."<p align="right"><span style="color:#747474">- Keith Wilson, MD</span></em></div></p>
Latest:
Updated Data Support Efficacy of Larotrectinib, Entrectinib in NSCLCAlexander Drilon, MD, discussed updated findings with larotrectinib in <em>NTRK</em> fusion–positive tumors and entrectinib in <em>ROS1</em> fusion–positive NSCLC.<br />
Latest:
Testing Lesions Improves Diagnosis of MelanomaKnowledge of genetic expression of melanocytic lesions significantly reduced the number of indeterminate diagnoses made by dermatopathologists.
Latest:
Link Drawn Between Oral HPV and Risk of Head and Neck CancersPatients with a certain type of oral human papilloma virus (HPV) have an increased risk of developing head and neck squamous cell carcinoma, as well as oropharyngeal cancer, according to a new study.
Latest:
Incorporating Biologic Factors Into Breast Cancer StagingKelly K. Hunt, MD, professor of Surgery, and chair, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses incorporating biologic factors into breast cancer staging.
Latest:
The Potential of ADCs in the Treatment of Breast CancerTargeted therapy through the use of antibody drug conjugates holds great promise for the treatment of many malignancies, in particular, breast cancer.
Latest:
Single-Cell RNA Sequencing in Merkel Cell CarcinomaKelly Paulson, MD, PhD, a fellow at Seattle Cancer Care Alliance, discusses single-cell RNA sequencing in merkel cell carcinoma during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.
Latest:
Collaborative Approach to Specialty Pharmacy Improves Adherence to Oral OncolyticsThe growth of the oncology drug pipeline has fueled the emergence of new oral therapies. While these therapies make treatment more convenient, when compared with traditional infused chemotherapy regimens, they also present new challenges, particularly in the area of adherence.
Latest:
Post-Therapy Imaging in LymphomaKenneth R. Carson, MD, assistant professor, Division of Oncology, Washington University, discusses post-therapy imaging in lymphoma.
Latest:
Dr. Kenneth Wang on Forgoing Screening for Barrett's EsophagusKenneth Wang, MD, director of the Advanced Endoscopy Group and Esophageal Neoplasia Clinic, Mayo Clinic, discusses his opposition for Barrett's esophagus screening as a preventative measure for esophageal adenocarcinoma.
Latest:
Ianalumab Produces Encouraging Early Activity in Phase 1 Study of CLLKerry Rogers, MD, discusses the findings observed in the phase 1b study of ianalumab in combination with ibrutinib as treatment of patients with chronic lymphocytic leukemia on ibrutinib therapy.
Latest:
The Development of T-VEC for MelanomaKevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses the outlook for T-VEC for the treatment of patients with melanoma.
Latest:
Expert Highlights the Clinical Utility of RNA Sequencing Methods in CancerKevin Halling, MD, PhD, discussed the clinical utility of RNA-sequencing methods in patients with cancer at the 2019 Association for Molecular Pathology Annual Meeting and Expo. Halling says RNA sequencing is a very powerful diagnostic technique.
Latest:
How Genetic Testing Has Changed for Patients With Breast CancerKevin Hughes, MD, discusses how genetic testing has changed and how much testing should be done for patients with breast cancer.
Latest:
HR+/HER2- Metastatic Breast Cancer: An Evolving Treatment ParadigmClosing out his discussion on HR+/HER2- metastatic breast cancer, Kevin Kalinsky, MD, MS, highlights key takeaways and shares excitement for future evolutions in the treatment paradigm.
Latest:
Exploring Treatment Options for Patients with ALK-Mutated Lung CancerKevin M. Sullivan, MD, discusses the current treatment options for patients with lung cancer harboring an <em>ALK</em> mutation.
Latest:
Differences Among Ethnic Groups in Multiple MyelomaKevin R. Kelly, MD, PhD, discusses the differences seen between ethnic groups in multiple myeloma diagnosis and response to treatment.
Latest:
Highlighting a Current Challenge in Treating Patients With HCCKevin Staveley-O’Carroll, MD, PhD, discusses one of the challenges in treating patients with hepatocellular carcinoma and shares what he thinks are the next steps in overcoming this challenge.
Latest:
Updates to Radiation Therapy in Breast Cancer for NCCN GuidelineKilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses recent updates in radiation therapy for breast cancer as discussed in the NCCN guideline.
Latest:
Oncogenic TSHR Mutation in Papillary Thyroid CancerWe present a case of a 49-year-old woman with a pT4aN1B papillary thyroid cancer who underwent radical thyroidectomy with bilateral neck dissection and RAI I-131 ablation, but poorly tolerated TSH suppression therapy due to tachycardia. Rising thyroglobulin levels and lymph node mapping showed recurrent/progressive disease in the thyroid bed.
Latest:
Translating MAGNITUDE Trial Results Into Clinical PracticeKim N. Chi, MD, FRCPC, discusses how the findings from the phase 3 MAGNITUDE trial translate into everyday practice.
Latest:
Dr. Kimberly L. Blackwell on a Promising HER2 Breast Cancer TreatmentKimberly L. Blackwell, MD, professor of Medicine, assistant professor of Radiation Oncology, Duke Cancer Institute, discusses upcoming trials for the HER2-antibody margetuximab.
